Pegaspargase Injection

Category: Antineoplastic / Enzyme therapy
Form: Injectable solution for intravenous (IV) or intramuscular (IM) use

Uses:

• Primarily used in acute lymphoblastic leukemia (ALL), especially in pediatric and adult patients.

• Administered as part of multi-drug chemotherapy regimens for leukemia treatment.

Mechanism of Action:

• Pegaspargase is a pegylated form of L-asparaginase, an enzyme.

• It depletes the amino acid L-asparagine from the blood.

• Leukemic cells cannot synthesize L-asparagine efficiently, so depletion leads to inhibition of protein synthesis and cell death.

• Pegylation prolongs the half-life of the enzyme, allowing less frequent dosing and reduced immunogenicity compared to native asparaginase.

Administration:

• Given intravenously or intramuscularly, depending on protocol.

• Dosage is based on body surface area and treatment regimen.

• Often given every 1–2 weeks during induction or consolidation phases of chemotherapy.

Side Effects:

• Hematologic: thrombosis, bleeding, low platelet counts.

• Metabolic: hyperglycemia, hyperbilirubinemia, elevated liver enzymes.

• Hypersensitivity: allergic reactions, including anaphylaxis (less common due to pegylation).

• Other: pancreatitis, gastrointestinal upset, fever, fatigue.

Precautions:

• Monitor liver function, coagulation parameters, and pancreatic enzymes during therapy.

• Use cautiously in patients with history of pancreatitis, clotting disorders, or liver disease.

• Immediate medical attention is required for signs of allergic reaction.

Summary:
Pegaspargase Injection is a chemotherapy enzyme therapy used in acute lymphoblastic leukemia. It works by depleting L-asparagine, starving leukemic cells of a vital amino acid, which inhibits protein synthesis and induces cell death. Pegylation allows longer action and fewer allergic reactions compared to native L-asparaginase. Side effects include liver toxicity, clotting abnormalities, hyperglycemia, pancreatitis, and rare allergic reactions.